Скачать или смотреть The Promise of Precision Cancer Treatment | Presented by CTCA and Foundation Medicine

After many rounds of chemo, radiation and surgery, Christine Bray was told she had one month to live. Then, doctors looked at her cancer’s DNA — and found its Achilles’ heel.

To learn more, visit: https://paidpost.nytimes.com/ctca-fou...

-----------------------------------------------------------------------------------------------------------

Check out more content from T Brand Studio:
Website: http://www.tbrandstudio.com/
Twitter:   / tbrandstudio  
Facebook:   / tbrandstudio  
Instagram:   / tbrandstudio  

T Brand Studio is the brand marketing unit of The New York Times. We create content and experiences that spark imaginations and influence the most influential audiences around the world. The news and editorial staffs of The New York Times had no role in this post's preparation.

-----------------------------------------------------------------------------------------------------------

FoundationOne®, FoundationOne®Heme, and FoundationOne CDx™ are diagnostic tests to identify genomic mutations associated with your cancer. This information, along with other information, may be used by your physician to identify potential treatment options. But these diagnostic tests do not confer any therapeutic benefit. The tests might not identify therapies that could be of benefit to you and you might not have positive outcomes with therapies identified through these tests. The outcomes described in this video are not typical and you should not expect to experience similar results. Consult your doctor about whether diagnostic testing is appropriate for you. Treatment decisions are the responsibility of your physician. These tests are available by prescription only.

FoundationOne CDx™ is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. For the complete intended use statement, including companion diagnostic indications and warnings and limitations, please see the FoundationOne CDx Technical Information, www.foundationmedicine.com/f1cdx.